Breaking Finance News

Zacks Investment Research upgraded Insys Therapeutics Inc (NASDAQ:INSY) to Hold in a report released earlier today.

Zacks Investment Research has upgraded Insys Therapeutics Inc (NASDAQ:INSY) to Hold in a statement released on 9/22/2016.

Boasting a price of $13.27, Insys Therapeutics Inc (NASDAQ:INSY) traded -3.49% lower on the day. With the last stock price close down -13.35% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Insys Therapeutics Inc has recorded a 50-day average of $15.76 and a two hundred day average of $15.32. Volume of trade was up over the average, with 1,191,965 shares of INSY changing hands over the typical 811,777

Performance Chart

Insys Therapeutics Inc (NASDAQ:INSY)

With a total market value of $0, Insys Therapeutics Inc has price-earnings ratio of 19.98 with a one year low of $11.45 and a one year high of $33.88 .

A total of 5 analysts have released a research note on Insys Therapeutics Inc. One equity analyst rating the company a strong buy, three firms rating the stock a buy, 1 brokerage rating the stock a hold, 0 brokers rating the company a underperform, and finally 0 firms rating the company a sell with a one year target of $24.40.

Brief Synopsis About Insys Therapeutics Inc (NASDAQ:INSY)

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *